Angiosyn Overview

  • Founded
  • 2003
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $527M
Latest Deal Amount

Angiosyn General Information

Description

Operator of a biopharmaceutical company developing novel proprietary biologics for controlling angiogenesis. The company's initial therapeutic indication is for ophthalmic diseases, such as macular degeneration and diabetic retinopathy, which due to angiogenesis can lead to decreased vision and blindness

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 3333 North Torrey Pines Court
  • Suite 150, La Jolla
  • San Diego, CA 92037
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Angiosyn Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 05-May-2005 $527M 000 00000 Completed Startup
2. Early Stage VC (Series A) 19-Oct-2004 000 000 000 Completed Startup
1. Early Stage VC (Series A) 27-May-2003 $1M $1M 000 Completed Startup
To view Angiosyn’s complete valuation and funding history, request access »

Angiosyn Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00 00 00 00 000
To view Angiosyn’s complete cap table history, request access »

Angiosyn Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alta Partners Venture Capital Minority 000 0000 000000 0
To view Angiosyn’s complete investors history, request access »